Proposal for a modified grading system based on mitotic index and Bcl2 provides objective determination of clinical outcome for patients with breast cancer

Journal of Pathology

Volumn 222, Issue 4, 2010, Pages 388-399

  Abdel Fatah, Tarek Ma ^a,b   Powe, Desmond G ^a   Ball, Graham ^c   Lopez Garcia, Maria A ^d   Habashy, Hany O ^a   Green, Andrew R ^a   Reis Filho, Jorge S ^d   Ellis, Ian O ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b MENOUFIA UNIVERSITY   (Egypt)

^c NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Bcl2; Breast cancer; Grading system; Mitotic index; Nottingham Prognostic Index; Predictive and prognostic marker

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROTEIN BCL 2;

ACCURACY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MITOSIS INDEX; NOTTINGHAM PROGNOSTIC INDEX; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE RISK; SCORING SYSTEM; TUMOR VOLUME;

AGED; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; MITOTIC INDEX; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 78349254920     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2775     Document Type: Article

References (32)

1. Elston CW, Ellis IO,. Pathological prognostic factors in breast cancer: I. The value of histologic grade in breast cancerexperience from a large study with long-term follow up. Histopathology 1991; 19: 403 - 410.
2. Rakha EA, El-Sayed ME, Lee AH, et al., Prognostic significance of Nottingham histologic grade in invasive breast cancer. J Clin Oncol 2008; 26: 3153 - 3158.
3. Ignatiadis M, Sotiriou C,. Understanding the molecular bases of histologic grade. Pathobiology 2008; 75: 104 - 111.
4. Singletary SE, Allred C, Ashley P, et al., Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002; 20: 3628 - 3636.
5. Desmedt C, Haibe-Kains B, Wirapati P, et al., Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 2008; 14: 5158 - 5165.
6. Abdel-Fatah TM, Powe DG, Hodi Z, et al., Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family. Am J Surg Pathol 2008; 32: 513 - 523.
7. Blamey RW, Ellis IO, Pinder SE, et al., Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999. Eur J Cancer 2007; 43: 548 - 555.
8. Tan DS, Marchió C, Jones RL, et al., Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 2008; 111: 27 - 44.
9. Marchió C, Iravani M, Natrajan R, et al., Mixed micropapillary-ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components. J Pathol 2009; 218: 301 - 315.
10. Callagy GM, Pharoah PD, Pinder SE, et al., Bcl2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res 2006; 12: 2468 - 2475.
11. Wolff AC, Hammond ME, Schwartz JN, et al., American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118 - 145.
12. Caffo O, Doglioni C, Veronese S, et al., Prognostic value of p21 (WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clin Cancer Res 1996; 2: 1591 - 1599.
13. Holm S,. A simple sequentially rejective multiple test procedure. Scand J Stat 1979; 6: 65 - 70.
14. Goldhirsch A, Wood WC, Gelber RD, et al., Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18: 1133 - 1144.
15. Roylance R, Gorman P, Harris W, et al., Comparative genomic hybridization of breast tumours stratified by histological grade reveals new insight into the biological progression of breast cancer. Cancer Res 1999; 59: 1433 - 1436.
16. Ellsworth RE, Hooke JA, Love B, et al., Correlation of levels and patterns of genomic instability with histological grading of invasive breast tumours. Breast Cancer Res Treat 2008; 107: 259 - 265.
17. Sotiriou C, Wirapati P, Loi S, et al., Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006; 98: 262 - 272.
18. Ivshina AV, George J, Senko O, et al., Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 2006; 66: 10292 - 10301.
19. Ma XJ, Salunga R, Tuggle JT, et al., Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A 2003; 100: 5974 - 5979.
20. Wirapati P, Sotiriou C, Kunkel S, et al., Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008; 10: R65.
21. Paik S, Shak S, Tang G, et al., A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817 - 2826.
22. Wang Y, Klijn JG, Zhang Y, et al., Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005; 365: 671 - 679.
23. Baak JP, van Diest PJ, Voorhorst FJ, et al., Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years. J Clin Oncol 2005; 23: 5993 - 6001.
24. Nathan B, Anbazhagan R, Clarkson P, et al., Expression of bcl-2 in the developing human fetal and infant breast. Histopathology 1994; 24: 73 - 76.
25. Reed JC,. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994; 124: 1 - 6.
26. Quinn CM, Ostrowski JL, Harkins L,. Loss of bcl-2 expression in ductal carcinoma in situ of the breast relates to poor histological differentiation and to expression of p53 and c-erbB-2 proteins. Histopathology 1998; 33: 531 - 536.
27. Sierra A, Castellsagué X, Escobedo A, et al., Bcl-2 with loss of apoptosis allows accumulation of genetic alterations: a pathway to metastatic progression in human breast cancer. Int J Cancer 2000; 89: 142 - 147.
28. Teixeira C, Reed JC, Pratt MA,. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 1995; 55: 3902 - 3907.
29. O'Reilly LA, Huang DC, Strasser A,. The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. EMBO J 1996; 15: 6979 - 6990.
30. William GH, Stoeber K,. Cell cycle markers in clinical oncology. Curr Opin Cell Biol 2007; 19: 672 - 679.
31. Simpson PT, Reis-Filho JS, Gale T, et al., Molecular evolution of breast cancer. J Pathol 2005; 205: 248 - 254.
32. Natrajan R, Lambros MB, Geyer FC, et al., Loss of 16q in high grade breast cancer is associated with estrogen receptor status: evidence for progression in tumors with a luminal phenotype? Genes Chromosomes Cancer 2009; 48: 351 - 365.